MRVI MARAVAI LIFESCIENCES HOLDINGS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1823239 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY10.8%
TTM net income YoY45.8%
TTM EPS YoY47.6%
Revenue 3-yr CAGR-20.2%
Net income 3-yr CAGR—
Margins
Gross margin39.1%
Operating margin-45.4%
Net margin-30.8%
FCF margin-5.9%
EBITDA margin-35.1%
Returns
ROE-29.8%
ROA-9.1%
ROIC (approx.)-27.0%
Asset turnover0.29x
Leverage & solvency
Liabilities / assets43.3%
Debt / equity0.75x
Current ratio4.66x
Interest coverage-4.57x
Cash quality & payout
Operating cash flow / net income0.08x
Accruals ratio-8.4%
Payout ratio—
Capex / revenue3.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $185.74M | $259.19M | $288.94M | $883.00M | $799.24M |
| Cost of revenue | $151.75M | $150.88M | $148.74M | $168.96M | $140.56M |
| Gross profit | $33.99M | $108.31M | $140.20M | $714.04M | $658.68M |
| R&D expense | $17.40M | $19.22M | $17.28M | $18.37M | $15.22M |
| SG&A expense | $145.12M | $161.77M | $151.39M | $129.26M | $100.06M |
| Operating income | -$215.27M | -$235.62M | -$31.65M | $574.22M | $554.64M |
| Interest expense | $26.99M | $47.70M | $45.89M | $20.41M | $30.26M |
| Pretax income | -$234.97M | -$261.48M | $617.74M | $551.47M | $530.76M |
| Income tax | -$4.21M | -$1.86M | $756.11M | $60.81M | $61.52M |
| Net income | -$130.77M | -$144.85M | -$119.03M | $220.21M | $182.04M |
| EBITDA | -$191.71M | -$214.76M | -$18.75M | $581.78M | $561.06M |
| EPS (basic) | -0.90 | -1.05 | -0.90 | 1.67 | 1.59 |
| EPS (diluted) | -0.90 | -1.05 | -0.90 | 1.67 | 1.56 |
| Weighted avg. shares (diluted) | 144.36M | 137.91M | 131.92M | 255.32M | 257.80M |
| Balance sheet | |||||
| Cash & equivalents | $216.89M | $322.40M | $574.96M | $632.14M | $551.27M |
| Receivables | $25.50M | $38.52M | $54.60M | $138.62M | $117.51M |
| Inventory | $40.49M | $50.08M | $51.40M | $43.15M | $51.56M |
| Current assets | $296.25M | $429.15M | $699.91M | $847.90M | $740.04M |
| PP&E, net | $151.48M | $164.47M | $162.90M | $52.69M | $46.33M |
| Goodwill | $129.43M | $159.88M | $326.03M | $283.67M | $152.77M |
| Intangibles | $151.54M | $194.96M | $220.99M | $216.66M | $117.57M |
| Total assets | $770.58M | $1.01B | $1.49B | $2.28B | $1.92B |
| Current liabilities | $44.92M | $56.97M | $87.47M | $110.14M | $93.78M |
| Short-term debt | $5.44M | $5.44M | $5.44M | $5.44M | $6.00M |
| Long-term debt | $286.33M | $290.49M | $518.71M | $522.00M | $524.59M |
| Total debt | $291.77M | $295.93M | $524.15M | $527.44M | $530.59M |
| Total liabilities | $397.87M | $431.04M | $697.57M | $1.38B | $1.37B |
| Shareholders' equity | $212.38M | $325.29M | $416.75M | $545.22M | $315.50M |
| Net debt | $74.88M | -$26.47M | -$50.81M | -$104.70M | -$20.68M |
| Cash flow statement | |||||
| Operating cash flow | -$57.57M | $7.46M | $126.22M | $535.98M | $368.57M |
| Capital expenditure | $13.15M | $29.66M | $65.55M | $17.09M | $14.85M |
| Free cash flow | -$70.72M | -$22.19M | $60.67M | $518.89M | $353.72M |
| Investing cash flow | -$31.41M | -$24.32M | -$122.31M | -$267.61M | $105.66M |
| Financing cash flow | -$16.50M | -$235.71M | -$61.09M | -$187.50M | -$159.05M |
| Depreciation & amortization | $23.56M | $20.85M | $12.90M | $7.57M | $6.41M |
| Stock-based compensation | $30.17M | $49.41M | $34.59M | $18.67M | $10.46M |
| Share buybacks | — | — | — | $0 | $0 |
Free plan shows the latest 5 periods; Pro shows all 7 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.